

ABSTRACT

Cancer Invest. 2022 Sep 14;1-35. doi: 10.1080/07357907.2022.2125004. Online ahead of print.

CAR-T cell therapy for solid tumors: are we still that far? A systematic review of literature.

Karam A(1), Mjaess G(2), Martinez Chanza N(3), Aoun F(1), Bou Kheir G(2), Younes H(1), Kazzi H(4), Albisinni S(2), Roumeguère T(2)(5).

Author information:

(1)Hotel-Dieu de France, University of Saint Joseph, Faculty of Medicine, Beirut, Lebanon.

(2)Department of Urology, Hôpital Universitaire de Bruxelles, Hôpital Érasme, Université Libre de Bruxelles, Brussels, Belgium.

(3)Department of Medical Oncology, Hôpital Universitaire de Bruxelles, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

(4)Department of Radiology, Saint Joseph Medical Center, Beirut, Lebanon.

(5)Department of Urology, Hôpital Universitaire de Bruxelles, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

This systematic review aims to assess all the prospective studies published to date on the efficacy of CAR-T cell therapy in solid tumors. Databases searched were PubMed and Google Scholar from inception through May 1st 2021. Search query was: (Chimeric antigen receptor)or(CAR-T)or(T-CAR). Twenty-nine prospective studies (265 patients) were included. Most published clinical trials are phase I. Clinical benefit was 100% in epithelial ovarian cancer, 70-82% in gastrointestinal tumors, 79% in mesothelioma, 63% in small-cell lung cancer, 24-67% in sarcoma, 50-62% in prostate cancer, and 45-50% in central nervous system tumors. No serious CAR-T cell specific serious toxicities were noted.

DOI: 10.1080/07357907.2022.2125004

PMID: 36102932